南新制药上半年净利亏损4000.23万元

Group 1 - The core viewpoint of the article highlights that Nanjing Pharmaceutical (688189) reported a significant decline in revenue and a shift to net loss in the first half of the year [1] Group 2 - The company achieved operating revenue of 61.8463 million yuan, a year-on-year decrease of 71.28% [1] - The net profit attributable to shareholders was -40.0023 million yuan, indicating a transition from profit to loss compared to the previous year [1] - The decline in performance is attributed to factors such as industry policy environment, intensified market competition, and a decrease in sales of high-margin products due to lower flu cases and insufficient market demand [1] - Despite the downturn, the company continued to invest a significant amount in research and development to enhance its core competitiveness [1]